Nucleic acid prodrugs and methods of use thereof
Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.
1. An oligonucleotide composition comprising a plurality of oligonucleotides of the following structure:
wherein:
each X-phosphonate independently has an Rp or Sp configuration;
R 1 is —OH, or —OR a ;
R a is a blocking group;
each instance of R 2 is independently hydrogen, —OH, -halogen, or —OR b , wherein R b is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase, wherein each modified nucleobase is independently adenine, cytosine, guanine, thymine or uracil, modified by one or more modifications:
(1) a nucleobase is modified by one or more groups independently selected from acyl, halogen, amino, azide, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, heteroaryl, carboxyl, hydroxyl, biotin, avidin, streptavidin, substituted silyl, and combinations thereof;
(2) one or more atoms of a nucleobase are independently replaced with a different atom selected from carbon, nitrogen or sulfur;
(3) one or more double bonds in a nucleobase are independently hydrogenated; or
(4) one or more aryl or heteroaryl rings are independently inserted into a nucleobase; or is independently selected from uracil, thymine, adenine, cytosine, and guanine having their respective amino groups protected by acyl groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pseudoisocytosine, pseudouracil, 8-substituted purines, xanthine, hypoxanthine;
or a modified nucleobase is a group selected from one of the following groups:
(1)
(2) corrin or porphyrin, each optionally modified by one or more groups independently selected from acyl, halogen, amino, azide, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, heteroaryl, carboxyl, hydroxyl, biotin, avidin, streptavidin, substituted silyl, and combinations thereof;
(3) phenanthrene, pyrene, stillbene, isoxanthine, isozanthopterin, terphenyl, terthiophene, benzoterthiophene, coumarin, lumazine, tethered stillbene, benzo-uracil, or naphtho-uracil, each optionally modified by one or more groups independently selected from acyl, halogen, amino, azide, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, heteroaryl, carboxyl, hydroxyl, biotin, avidin, streptavidin, substituted silyl, and combinations thereof;
(4) 3-nitropyrrole, 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine, or a nucleobase of 4-acetylcytidine; 5-(carboxyhydroxylmethyl)uridine; 2′-O-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; dihydrouridine; 2′-O-methylpseudouridine; beta,D-galactosylqueosine; 2′-O-methylguanosine; N6-isopentenyladenosine; 1-methyladenosine; 1-methylpseudouridine; 1-methylguanosine; 1-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N7-methylguanosine; 3-methyl-cytidine; 5-methylcytidine; N6-methyladenosine; 7-methylguanosine; 5-methylaminoethyluridine; 5-methoxyaminomethyl-2-thiouridine; beta,D-mannosylqueosine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 2-methylthio-N6-isopentenyladenosine; N-((9-beta,D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine; N-((9-beta,D-ribofuranosylpurine-6-yl)-N-methylcarbamoyl)threonine; uridine-5-oxyacetic acid methylester; uridine-5-oxyacetic acid (v); pseudouridine; queosine; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2′-O-methyl-5-methyluridine; or 2′-O-methyluridine; and
(5) heteroaryl or heterocyclyl optionally substituted with one or more groups independently selected from acyl, halogen, amino, azide, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, heteroaryl, carboxyl, hydroxyl, biotin, avidin, streptavidin, substituted silyl, and combinations thereof;
at least one X moiety is selected from —OCH 2 CH 2 S—S(O) 2 R 10 , OCH 2 CH 2 S—SCH 2 CH 2 OH, —OCH 2 CH 2 CO 2 H,
wherein:
R 8 is a linear or branched alkyl, aryl, aralkyl, or aryloxylalkyl group having 1 to 15 carbon atoms,
R 9 is an alkyl group having 1 to 4 carbon atoms;
R 10 is an alkyl group having 1 to 4 carbon atoms;
R 11 is alkyl, aryl, heteroaryl, heterocyclyl, or cycloalkyl;
R 12 is hydrogen or alkyl;
R 3 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;
n is an integer of 10 to about 200; and
the composition is stereodefined.
2. The composition of claim 1 , wherein the composition is stereodefined in that each X-phosphonate moiety is more than 98% diastereomerically pure within the composition as determined by 31 P NMR spectroscopy or reverse-phase HPLC.
3. The composition of claim 1 , wherein at least one instance of X is selected from
4. The composition of claim 1 , wherein at least 25% of the X moieties are independently selected from
5. The composition of claim 1 , wherein each X moiety is independently selected from
6. The composition of claim 1 , wherein n is an integer of 15 to about 200.
7. The composition of claim 1 , wherein n is an integer of 20 to about 200.
8. The composition of claim 1 , wherein R 1 is —OH.
9. The composition of claim 1 , wherein each instance of R 2 is independently hydrogen, halogen, or —OR b .
10. The composition of claim 8 , wherein each instance of R 2 is independently hydrogen, halogen, or —OR b .
11. The composition of claim 8 , wherein at least one R 2 is hydrogen.
12. The composition of claim 8 , wherein at least one R 2 is halogen.
13. The composition of claim 8 , wherein at least one R 2 is —OR b .
14. The composition of claim 12 , wherein R b is methyl.
15. The composition of claim 1 , wherein R 3 is hydrogen.
16. The composition of claim 10 , wherein R 3 is hydrogen.
17. The composition of claim 1 , wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine.
18. The composition of claim 8 , wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine.
19. The composition of claim 10 , wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine.
20. The composition of claim 16 , wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine.